Skip to main navigation
Skip to search
Skip to main content
The UWS Academic Portal Home
Help & FAQ
Link opens in a new tab
Search content at The UWS Academic Portal
Home
Profiles
Research units
Research output
Activities
Press/Media
Projects
Prizes
Radionuclides landscape in prostate cancer theranostics
Monica Neagu
*
, Carolina Constantin
, Mihail Eugen Hinescu
, Petrisor Gabriel Bleotu
, Mara-Georgiana Popovici
, Maria-Iulia Zai
, Klaus Michael Spohr
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Review article
›
peer-review
33
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Radionuclides landscape in prostate cancer theranostics'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Prostate Cancer Theranostics
100%
Novartis
66%
Radiotheranostics
66%
PSMA-11
33%
Taxane-based Chemotherapy
33%
212Pb
33%
PSMA-617
33%
Radionuclide 177Lu
33%
Androgen Signaling
33%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
33%
149Tb
33%
125I
33%
Clinical Implementation
33%
Pathway Targeting
33%
Radiodiagnostics
33%
Ga-PSMA
33%
161Tb
33%
18F-DCFPyL
33%
Prostate Radiotherapy
33%
211At
33%
227Th
33%
Targeted Agents
33%
Zirconium-89 (89Zr)
33%
Lutetium-177 (177Lu)
33%
Gallium-68
33%
Pharmacology, Toxicology and Pharmaceutical Science
Radioisotope
100%
Fluorine 18
50%
Actinium 225
50%
Lutetium 177
50%
Iodine-125
25%
Bismuth 213
25%
Taxane
25%
Zirconium 89
25%
Gallium 68
25%
Castration Resistant Prostate Cancer
25%
Lead 212
25%
Medicine and Dentistry
Radioisotope
100%
Lutetium 177
50%
Fluorine-18
50%
Actinium 225
50%
Iodine 125
25%
Lead 212
25%
Zirconium 89
25%
Gallium 68
25%
Castration Resistant Prostate Cancer
25%
Bismuth 213
25%